A study of combination therapy for advanced liver cancer with spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced liver cancer (HCC) that cannot be removed by surgery and has spread to the main blood vessel of the liver (portal vein) or to a few other spots (up to 5 total, in up to 3 different organs).
- Your liver function is well enough (Child-Pugh class A) and you are able to do your daily activities (ECOG performance status 0 or 1).
- You have had no previous targeted immunotherapy (like PD-1/PD-L1 or CTLA-4 drugs) or certain other immunotherapies for liver cancer.
- You do not have active bleeding risk, such as untreated varices (swollen veins in the esophagus or stomach), recent bleeding, or need for strong blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This Phase 2 trial studies whether delivering an immunotherapy drug directly into the liver’s artery, together with bevacizumab, can shrink advanced hepatocellular carcinoma. You may be considered if prior whole-body (systemic) treatment has not worked and prior local procedures were also not tolerated or failed.
This trial tests a combination of three treatments for advanced liver cancer (BCLC stage C): HAIC (chemotherapy directly into the liver), adebrelimab (immunotherapy that helps your immune system fight cancer), and apatinib (a targeted drug that cuts off blood supply to tumors). It may be an option if you have not had any prior systemic (whole-body) therapy for liver cancer.
This trial tests a combination of three drugs—an immunotherapy (TQB2450), a targeted therapy (anlotinib), and a repeat HAIC infusion—for people whose advanced liver cancer has worsened after a first treatment. It may be an option if you've already had HAIC with platinum and are now looking for a new approach.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.